Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
GlobalData on MSN3d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...
The trial demonstrated that Enhertu, a HER2-directed antibody drug conjugate (ADC), significantly reduced the risk of disease progression or death by 38% compared to chemotherapy, achieving a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback